A5083054969- Gut microbiota and health
- Inflammatory Bowel Disease
- Microscopic Colitis
- Cancer Immunotherapy and Biomarkers
- Clostridium difficile and Clostridium perfringens research
- Helicobacter pylori-related gastroenterology studies
- Diverticular Disease and Complications
- Autoimmune and Inflammatory Disorders
- Gastrointestinal motility and disorders
- Neuroscience and Neuropharmacology Research
- Vitamin D Research Studies
- IgG4-Related and Inflammatory Diseases
- Diagnosis and treatment of tuberculosis
- Mycobacterium research and diagnosis
- Pancreatitis Pathology and Treatment
- Gastrointestinal disorders and treatments
- Pancreatic and Hepatic Oncology Research
- Epilepsy research and treatment
- Neuroendocrine Tumor Research Advances
- Digestive system and related health
- Probiotics and Fermented Foods
- Colorectal Cancer Screening and Detection
- Inflammasome and immune disorders
- Tryptophan and brain disorders
- Pain Mechanisms and Treatments
Peking Union Medical College Hospital
2016-2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2016-2025
University of South China
2019-2024
Zhejiang Chinese Medical University
2021-2024
China Pharmaceutical University
2021-2023
Universiti of Malaysia Sabah
2023
Central South University
2017-2022
Zhejiang Medicine (China)
2022
Third Xiangya Hospital
2017-2022
John Wiley & Sons (United States)
2021
Roseburia intestinalis (R. intestinalis) is one of the dominant intestinal bacterial microbiota and decreased in patients with inflammatory bowel disease (IBD). It helps protect colonic mucosa against development inflammation subsequent IBD, however its underlying mechanisms are unclear. The aim present study was to evaluate anti‑inflammatory properties R. vitro an animal model IBD. effects on activity index (DAI) scores, pathology, expression interleukin (IL)‑17 frequency CD4+CD25+Foxp3+...
The study aims to elucidate the anti-inflammatory effect and mechanism of Roseburia intestinalis (R. intestinalis) in Crohn's disease (CD).16S-rRNA genome sequencing technique is used detect characteristics intestinal microbiota untreated CD patients healthy controls. Then investigates effects R. on activity index score, pathology, differentiation Treg cells, expressions Thymic stromal lymphopoietin (TSLP), TGF-β IL-10 by using TNBS colitis models. At cellular level, uses LPS stimulate...
Long-term pharmacotherapy, serving as the main therapeutic approach for epilepsy prophylaxis, has suffered from limited efficacy and potential side effects because of blood-brain barrier (BBB) untimely medication. Here, we reported a nanoengineered drug delivery system synergistic brain-targeting on-demand release antiepileptic drugs (AEDs). The dopamine-pyrrole hybrid can improve efficiency through combination receptor-mediated transcytosis BBB disruption–enabled transport induced by...
BackgroundCrohn's disease (CD) is a chronic inflammatory disorder characterized by intestinal immune dysfunction. Multiple factors, including gut dysbiosis, are involved in the pathogenesis of CD. However, effect commensal bacteria on controlling response individuals with CD remains unclear.MethodsWe detected Toll-like receptor 2 (TLR2), TLR4, and TLR5 expression Roseburia intestinalis (R. intestinalis)-treated mice 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis. Then, we...
Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD), which chronic, relapsing condition associated with the disorder gut microbial communities. A previous study reported that levels Roseburia intestinalis (R.I), butyrate‑producing bacterium, are significantly decreased in patients IBD and exert an anti‑inflammatory function dextran sulfate sodium (DSS)‑induced colitis. However, role R.I flagellin UC its underlying molecular mechanism not yet fully understood. Therefore,...
Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's (CD), has a complex etiology that may be associated with dysbiosis of the microbiota. Previously, our study revealed significant loss Roseburia intestinalis from gut untreated patients CD, R. exerted anti‑inflammatory functions in TNBS‑induced colitis; however, function supernatant is unknown. Therefore, LPS‑induced macrophages, including RAW264.7 macrophages bone marrow‑derived were treated supernatant. The...
Objective Unidentified mechanisms largely restrict the viability of effective therapies in pharmacoresistant epilepsy. Our previous study revealed that hyperactivity subiculum is crucial for genesis pharmacoresistance temporal lobe epilepsy (TLE), but underlying molecular mechanism not clear. Methods Here, we examined role subicular caspase‐1, a key neural pro‐inflammatory enzyme, TLE. Results We found expression activated caspase‐1 subiculum, CA1, was upregulated amygdaloid‐kindled rats....
The gut microbiota is implicated in the occurrence and severity of immune-related adverse events (irAEs), but role it plays as well its causal relationship with irAEs has yet to be established.From May 2020 August 2021, 93 fecal samples were prospectively collected from 37 patients advanced thoracic cancers treated anti-PD-1 therapy, 61 33 various developing different irAEs. 16S rDNA amplicon sequencing was performed. Antibiotic-treated mice underwent transplantation (FMT) without colitic...
Immune checkpoint inhibitor (ICI) has been widely used in lung cancer patients. While ICI treatment improves the overall survival of patients, it can also lead to a series immune-related adverse events (irAE). Severe irAE should be treated with glucocorticoids and biological agents. Opportunistic infections highly vigilant during We report patient locally advanced non-small cell who developed severe ICI-related colitis after chemotherapy combined immunotherapy. The hematogenous disseminated...
Abstract Aims Temporal lobe epilepsy (TLE), often associated with cognitive impairment, is one of the most common types medically refractory epilepsy. Deep brain stimulation (DBS) shows considerable promise for treatment TLE. However, optimal targets and parameters DBS to control seizures related impairment are still not fully illustrated. Methods In present study, we evaluated therapeutic potential in medial septum (MS) on function mouse acute chronic models. Results We found that MS...
Background Clostridium difficile infection (CDI) is common in patients with inflammatory bowel disease (IBD) and has been reported as a risk factor for poor outcome. However, gut microbiome mycobiome of IBD CDI have barely investigated. This study aimed to assess the CDI. Methods We collected fecal samples from active concomitant (IBD-CDI group, n=25), no (IBD-only n=51), healthy subjects (HC, n=40). Patients’ characteristics including demographic data, severity, medication history were...
We aimed to investigate the serum 25-hydroxyvitamin D3 (25[OH]D3 ) levels and bone metabolism in adult Chinese patients with inflammatory bowel disease (IBD) evaluate correlation between vitamin D activity as well potential risk factors.Age- gender-matched cohort of IBD (124 ulcerative colitis [UC] 107 Crohn's [CD]) 122 healthy controls were enrolled this study. Serum 25(OH)D3 mineral density (BMD) measured, two parameters severity clinical factors analyzed.Serum lower UC (10.32 ± 4.46...
Objective: Levels of oncostatin M (OSM) and the composition gut microbiota predict responses to anti-TNF agents used for IBD therapy. Here, aim was investigate effects Roseburia intestinalis, a microbiota, on OSM intestinal barrier in colitis. Methods: In murine model 3% dextran sulfate sodium (DSS)-induced colitis, we tested disease activity index (DAI), colon length, histological score expression tight junction (TJ) proteins (ZO-1, occludin claudin-1), OSM, TNF-α TLR5. addition, cellular...
OBJECTIVE To assess the necessity and efficacy of vitamin D (VitD) supplementation in Chinese ulcerative colitis (UC) Crohn’s disease (CD) patients with insufficiency/deficiency. METHODS UC CD were randomly assigned into one three arms for 12 months: arm A (VitD 3 150 000 IU once per months plus elemental calcium 200 mg thrice daily), B (elemental daily) C (vehicle control group), addition to conventional treatment. Improvement 25‐hydroxyvitamin [25(OH)D] level was primary outcome study....
Cisplatin is a chemotherapeutic agent widely employed in the treatment of various solid tumors. However, its use often restricted by acute kidney injury (AKI) which dose-limiting adverse effect cisplatin. While numerous studies aiming to alleviate AKI have been conducted, there are no effective remedies clinical practice. In this paper, targeted metabolomics study was performed reveal potential relationship between tryptophan metabolism and cisplatin-induced AKI. A chemical derivatization...
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer immunotherapy, but secondary resistance (SR) and immune-related adverse events (irAEs) are significant clinical dilemmas. Although the gut microbiota is associated with ICI efficacy irAEs, knowledge of longitudinal dynamics during SR irAE development still quite limited.This was prospective observational cohort study patients initially receiving anti-programmed cell death-1 (PD-1) treatment between May 2020 October 2022....